Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.

Catalyst Pharmaceuticals is focused on developing therapies for rare and ultra-rare diseases.

Metric
Company Name	Catalyst Pharmaceuticals, Inc.	BioMarin Pharmaceutical Inc.
Symbol	CPRX	BMRN
MSH ID	COM:CATALYSTPHARMA	COM:BIOMARIN
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	167	3.40K
Website	catalystpharma.com	biomarin.com
LinkedIn		biomarin
Founders

Metric
Market Cap	1.83B	15.63B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	398.20M	2.42B
Revenue (LTM)
Revenue (NTM)
Gross Profit	313.67M	1.84B
EBITDA	119.95M	261.98M
Operating Income	86.81M	157.60M
Net Income	71.41M	167.65M
EPS	0.67	0.87
Diluted EPS	0.63	0.87
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.85	0.79
Operating Profit Margin	0.22	0.09
EBITDA Margin	0.30	0.11
Net Profit Margin	0.18	0.10
Return on Equity	0.20	0.05
Return on Assets	0.15	0.04
Return on Capital Employed	0.22	0.04

COM:CATALYSTPHARMA

Catalyst Pharmaceuticals, Inc.

Last Close

21.12

22/11 21:00

Market Cap

1.83B

Beta: -

Volume Today

863.01K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	23.01	112.42
P/B Ratio	4.10	3.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.92	6.93
EV Multiple	24.02	2.98K

Metric
Days Sales Outstanding	50.34	90.44
Days Payables Outstanding	35.44	217.10
Days Inventory Outstanding	114.51	791.48
Operating Cycle	168.19	888.78
Cash Conversion Cycle	109.30	888.78
Asset Turnover	0.84	0.37

Metric
Operating Cash Flow	143.60M	159.26M
Free Cash Flow	-54.92M	51.65M
Cash Flow to Debt	58.30	0.30
Operating Cash Flow/Sales	0.45	0.13
Free Cash Flow Yield	0.03	0.00

Metric
Cash & Equivalents	137.64M	755.13M
Accounts Receivable	-43.08M	-190.44M
Inventory	15.64M	1.11B
Goodwill		196.20M
Debt to Capitalization	0.01	0.18
Debt to Assets	0.01	0.16
Current Ratio	3.32	2.54
Quick Ratio	4.94	6.42K

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03	0.09
R&D to Revenue	0.27	0.31
SG&A to Revenue	0.12	0.19